Literature DB >> 28478205

Complete genome sequencing and clinical analysis of intrahepatic hepatitis B virus cccDNA from HCC.

Fengping Jiao1, Lu Long2, Shanlong Ding2, Xiaomeng Xie2, Le Jia3, Fengmin Lu4.   

Abstract

BACKGROUND: More than half of hepatocellular carcinomas (HCCs) are etiologically attributed to hepatitis B virus (HBV) infection, but it remains unclear whether HBV mutations are virological factors that contribute to formation of HCC or instead reflect accumulation during the progression of HBV-related disease.
METHODS: Rolling-cycle amplification and PCR sequencing were used to characterize covalently closed circular DNA (cccDNA) mutations in tumor tissues. Paired non-tumor tissues were used as controls.
RESULTS: High frequencies of C1653T, T1753V, and A1762T/G1764A cccDNA mutations were observed in both tumor and non-tumor tissues. T1719G, C1329A, and T3098C mutations were related to the overall survival of HCC patients. Patients with G1719 tended to be in the high Barcelona Clinic Liver Cancer stage and had lower levels of total DNA and cccDNA per cell than patients with T1719. Additionally, in vitro analysis revealed that T1719G mutation reduced viral replication efficacy. Finally, significantly higher levels of preoperative alpha-fetoprotein were observed in patients harboring the G1078T, C1653T, G1727A, C1913A, T1978C, or C3116T mutations at the cccDNA level.
CONCLUSIONS: We speculated that HBV cccDNA mutations accumulated over the course of HBV-related disease development, and that some key mutations had prognostic value for patients with HBV-related HCC.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatitis B virus; Hepatocellular carcinoma; Mutation; Survival; cccDNA

Mesh:

Substances:

Year:  2017        PMID: 28478205     DOI: 10.1016/j.micpath.2017.04.028

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  4 in total

1.  Antiviral therapy may decrease HBx, affecting cccDNA and MSL2 in hepatocarcinogenesis.

Authors:  Xue-Li Jin; Suk Kyun Hong; Hwajung Kim; Sun-Kyung Lee; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

Review 2.  Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy.

Authors:  Xiangyuan Luo; Xiaoyu Ji; Meng Xie; Tongyue Zhang; Yijun Wang; Mengyu Sun; Wenjie Huang; Limin Xia
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

3.  One case of iodine-125 therapy - A new minimally invasive treatment of intrahepatic cholangiocarcinoma.

Authors:  Xinju Chen; Xiaoqi Chen; Chuanlei Zhang; Xinting Wang; Changwei Yuan; He Yang; Lixia Yang
Journal:  Open Life Sci       Date:  2022-09-27       Impact factor: 1.311

4.  Complete genome analysis of hepatitis B virus in Qinghai-Tibet plateau: the geographical distribution, genetic diversity, and co-existence of HBsAg and anti-HBs antibodies.

Authors:  He Liu; Liping Shen; Shuang Zhang; Feng Wang; Guomin Zhang; Zundong Yin; Feng Qiu; Xiaofeng Liang; Fuzhen Wang; Shengli Bi
Journal:  Virol J       Date:  2020-06-12       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.